Medical Equipment

Positron Emission Tomography (PET) Radiotracer Market Developments and Growth Opportunities Across 2026–2030

March 16, 2026April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Positron Emission Tomography (PET) Radiotracer Market Evolve From 2026 To 2030?

The positron emission tomography (pet) radiotracer market size has experienced robust growth in recent years. It is projected to increase from $2.54 billion in 2025 to $2.78 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.2%. This historical expansion can be attributed to factors such as increasing cancer diagnosis rates, the growth of nuclear medicine facilities, the established application of FDG-based imaging, the availability of cyclotron infrastructure, and the development of diagnostic imaging services.

The positron emission tomography (pet) radiotracer market is projected to undergo significant expansion over the coming years. This sector is forecast to reach $3.95 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 9.2%. The anticipated growth during this period stems from factors such as increasing demand for precision diagnostics, rising investments in radiopharmaceutical R&D, expansion of theranostics applications, growing adoption of pet imaging in neurology and cardiology, and increasing regulatory approvals for new tracers. Key developments expected in the forecast period encompass increasing development of target-specific radiotracers, rising adoption of pet imaging in oncology diagnostics, growing use of novel isotopes beyond fdg, expansion of personalized nuclear medicine applications, and an enhanced focus on short-half-life radiotracer production.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19152&type=smp

What Major Drivers Are Influencing Demand In The Positron Emission Tomography (PET) Radiotracer Market?

The rising occurrence of infectious diseases is projected to drive the expansion of the positron emission tomography (PET) radiotracer market in the future. These diseases are defined as conditions resulting from pathogenic microorganisms like bacteria, viruses, fungi, or parasites. Their escalating prevalence stems from factors such as climate change, urbanization, globalization, antibiotic resistance, and shifts in human behavior, all of which contribute to pathogen dissemination. Positron emission tomography (PET) radiotracers aid in managing infectious diseases by allowing visualization of metabolic activity and inflammation, thereby facilitating infection detection, evaluating treatment efficacy, and distinguishing between infectious and non-infectious states to improve patient results. For example, a report from the UK Health Security Agency, a UK-based government agency, published in February 2024, indicated that tuberculosis (TB) cases in England saw a 10.7% rise in 2023, reaching 4,850 reported cases as opposed to 4,380 in 2022. Consequently, the expanding occurrence of infectious diseases is fueling the development of the positron emission tomography (PET) radiotracer market.

Which Segment Areas Are Covered In The Positron Emission Tomography (PET) Radiotracer Market Analysis?

The positron emission tomography (pet) radiotracer market covered in this report is segmented –

1) By Radiotracer Type: F-18 (Fluorodeoxyglucose 18), Ga-68 (Fibroblast Activation Protein Inhibitor), Other Radiotracer Types

2) By Application: Cancer, Heart Disease, Gastrointestinal, Endocrine, Neurological Disorders, Other Applications

3) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:

1) By F-18 (Fluorodeoxyglucose 18): F-18 FDG (Fluorodeoxyglucose), F-18 Fluoroethyltyrosine (FET), F-18 Florbetapir (Amyloid PET Imaging)

2) By Ga-68 (Fibroblast Activation Protein Inhibitor): Ga-68 Dotatate (Neuroendocrine Tumor Imaging), Ga-68 PSMA (Prostate-Specific Membrane Antigen Imaging), Ga-68 FAPI (Fibroblast Activation Protein Inhibitor Imaging)

3) By Other Radiotracer Types: C-11 (Carbon-11), N-13 (Nitrogen-13), O-15 (Oxygen-15), Rb-82 (Rubidium-82), I-124 (Iodine-124)

What Key Developments And Trends Are Impacting The Positron Emission Tomography (PET) Radiotracer Market?

Leading companies operating within the positron emission tomography (PET) radiotracer market are concentrating on developing advanced diagnostic solutions, such as positron emission tomography imaging agents, to improve cancer detection and enhance patient outcomes. A positron emission tomography (PET) imaging agent refers to a radioactive substance utilized to visualize and measure biological processes within the body during PET scans. For instance, in March 2023, IsoLogic Innovative Radiopharmaceuticals, a Canada-based radiopharmaceutical company, launched Illuccix, also known as the Ga-68 Gozetotide Preparation Kit (PSMA-11), in Canada. This product serves as a prostate cancer imaging agent specifically designed to detect metastatic prostate cancer. This tool proves valuable for physicians in identifying metastatic disease and supporting patient management decisions. It is indicated for use in patients with suspected metastasis who are candidates for initial definitive therapy, as well as in those with suspected recurrence evidenced by elevated serum prostate-specific antigen (PSA) levels.

Which Global Companies Are Actively Competing In The Positron Emission Tomography (PET) Radiotracer Market?

Major companies operating in the positron emission tomography (pet) radiotracer market are Cardinal Health Inc., GE Healthcare Technologies Inc., Bracco Imaging S.p.A., Lantheus Holdings Inc., Jubilant Pharma Limited, SOFIE Biosciences, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Nordion Inc., Isologic Innovative Radiopharmaceuticals, ABX Advanced Biochemical Compounds GmbH, IBA Radiopharma Solutions S.A., ImaginAb Inc., Radiomedix Inc., Curium Pharma, Blue Earth Diagnostics Ltd., Eckert & Ziegler Radiopharma GmbH, Advanced Accelerator Applications (Novartis), Telix Pharmaceuticals Limited, PETNET Solutions Inc., Piramal Imaging

Read the full positron emission tomography (pet) radiotracer market report here:

https://www.thebusinessresearchcompany.com/report/positron-emission-tomography-pet-radiotracer-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Positron Emission Tomography (PET) Radiotracer Market?

North America was the largest region in the positron emission tomography (PET) radiotracer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the positron emission tomography (pet) radiotracer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Positron Emission Tomography (PET) Radiotracer Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19152&type=smp

Browse Through More Reports Similar to the Global Positron Emission Tomography (PET) Radiotracer Market 2026, By The Business Research Company

Poc Medical Imaging Market Report 2026

https://www.thebusinessresearchcompany.com/report/poc-medical-imaging-global-market-report

Veterinary Imaging Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-imaging-global-market-report

Pet Tech Market Report 2026

https://www.thebusinessresearchcompany.com/report/pet-tech-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795